Changing the way immune-based cancer drugs are delivered could reduce costs by 14%

Using weight-based doses and sharing single-use vials could save millions of dollars annually

10:25 AM

Author | Nicole Fawcett

money pills cancer vial yellowArtboard
Credit: Justine Ross, Michigan Medicine

An analysis finds that up to millions of dollars could be saved annually on cancer immunotherapy treatments across the Veterans Health Administration by reconsidering how those drugs are delivered.

It’s a concept that could be applied to all cancer centers nationwide. Immune checkpoint inhibitors were initially tested and approved at weight-based dosages but then moved to one-size-fits-all flat doses, in part to reduce drug waste.

But researchers from the University of Michigan Rogel Cancer Center found that if vials intended for a single patient’s use are shared across patients, then physicians could deliver customized doses while also reducing waste and costs.

“Administering drugs in flat one-size-fits-all dosages is predictable and allows for single-use vials with less drug material being discarded. This gives the appearance of less waste to the payer,” said senior study author Garth W. Strohbehn, M.D., M.Phil., assistant professor of hematology/oncology at Michigan Medicine and an early career research scientist with the VA Ann Arbor Center for Clinical Management Research.

“But it conceals the fact that excess drug amounts may be administered to the patient, relative to what they need, which ultimately may be increasing usage and drug spending.”

To model the concept, researchers focused on data from the Veterans Health Administration, identifying records of patients who received at least one dose of any type of immune checkpoint inhibitor from a Veterans Affairs medical center in 2021 to create a simulation of how the drugs could be better stewarded.

This included using weight-based doses and combining single-use vials across multiple patients rather than discarding any extra among.

The VHA spends hundreds of millions of dollars per year on immune checkpoint inhibitors. The researchers found that combining weight-based dosing and single-use vial sharing within each VA hospital’s pharmacy would reduce immune checkpoint spending by 14%.

The study is published in Health Affairs.

“Evidence suggests that flat and weight-based dosing are equally effective in treating cancer. In an era of ever-rising drug prices and aging populations, adopting stewardship measures could markedly improve the cost-effectiveness of cancer care in our country,” said lead study author Alex Bryant, M.D., MAS, a radiation oncology resident at Michigan Medicine.

Additional authors: Zoey Chopra, Donna M. Edwards, Adam S. Whalley, Brian G. Bazzell, Julie A. Moeller, Michael J. Kelley, A. Mark Fendrick, Eve A. Kerr, Nithya Ramnath, Michael D. Green, Timothy P. Hofer

Funding for this work is from the Lung Precision Oncology Program (grant VA 150CU000182), LUNGevity, the Department of Veterans Affairs (grant I01 BX005267), the Melanoma Research Alliance, the National Cancer Institute (grants CA252010 and P30CA046592), the Breast Cancer Research Foundation

This work was supported by these Rogel Cancer Center Shared Resources.

Paper cited: “Adopting Weight-Based Dosing with Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending by Millions,” Health Affairs. DOI: 10.1377/hlthaff.2023.00102


More Articles About: All Research Topics Basic Science and Laboratory Research Cancer: Cancer Types Cancer: Help, Diagnosis & Treatment Future Think Hospitals & Centers
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories vial of blood with blue background cell floating
Health Lab
Hitting the mark
University of Michigan Rogel Cancer Center researchers are unraveling its nuances, advancing enabling technologies, advocating for patients and figuring out how to ethically integrate this technology into clinical care.
Jianping Fu, Ph.D., Professor of Mechanical Engineering at the University of Michigan and the corresponding author of the paper being published at Nature discusses his team’s work in their lab with Jeyoon Bok, Ph.D. candidate at the Department of Mechanical Engineering.
Health Lab
Human stem cells coaxed to mimic the very early central nervous system
The first organized stem cell culture model that resembles all three sections of the embryonic brain and spinal cord could shed light on developmental brain diseases
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Illustration of a microscope
Health Lab
Hippo signaling pathway gives new insight into systemic sclerosis
Study focuses on Hippo signaling pathway as critical link between fibrosis, vascular dysfunction, and sex bias in systemic sclerosis
Headshot of Anne Draelos
Research News
U-M's Anne Draelos named a 2024 Sloan Research Fellow in neuroscience
Anne Draelos, Ph.D., Assistant Professor of Biomedical Engineering and Computational Medicine & Bioinformatics, has been named a 2024 Sloan Research Fellow in Neuroscience.
Provider takes a pulse oximetry reading from a patient's finger
Health Lab
Inaccurate pulse oximeter readings could limit transplants, heart pumps for Black patients with heart failure
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heart failure to receive potentially lifesaving treatments, such as heart pumps and transplants